RWD18 Characterization of Time-to-Treatment-Discontinuation (TTTD) as a Proxy for Progression-Free Survival (PFS) in Real-World Evidence (RWE) Based Analyses of Relapsed-Refractory Multiple Myeloma (RRMM)
Abstract
Authors
J. O'Reilly A. Perkins F. Tunaru J. Wallis L. Carpenter